Company News: NEO New Oncology AG closes financing round

NEO New Oncology AG, a Cologne based cancer diagnostics company, today announced the closing of a financing round with a total investment of app. EUR 5 Million.

“I am pleased by the strong interest that NEO New Oncology AG has received from the investment community,” commented Dr Andreas Jenne, CEO of NEO New Oncology AG. “Together with the proceeds from the first closing earlier this year, the funds will help us to make NEOliquid, a genomic diagnostics test that identifies all therapeutically actionable genome alterations from a simple blood sample, available to patients even faster.”